Food and Drug Administration Drug Safety Podcast
FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions
- Author: Podcast
- Narrator: Podcast
- Publisher: Podcast
- Duration: 0:04:00
- More information
Informações:
Synopsis
Listen to an audio podcast of the September 1, 2021 FDA Drug Safety Communication on requiring revisions to the Boxed Warning for Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to include information about the risks of serious heart-related events, cancer, blood clots, and death.
